WaveMan
WaveMan · Company
TECX · Tectonic Therapeutic, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TECX Tectonic Therapeutic (TECX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001681087
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $3.8K priced

What the filings say about TECX

Insiders, 180 days
-$53.4K net sold
2 sellers · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$676.0K
4 notices

Tectonic Therapeutic insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Tectonic Therapeutic, Inc. insiders sold a net $53.4K of stock across 32 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
McNamara Peter
Chief Scientific Officer
SELL
2026-10-02 SECtraded 2026-09-30
536
$12.3K
-12.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 25, 2026.
  • The trade is 1.0% of the 54,305 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer McNamara Peter sold about $12.3K of TECX under a 10b5-1 plan on Sep 30, 2026; 64 funds added in the latest 13F quarter.
McNamara Peter
Chief Scientific Officer
SELL
2026-08-26 SECtraded 2026-08-25
43
$1.6K
-44.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 12, 2026.
  • The trade is 0.1% of the 55,285 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer McNamara Peter sold about $1.6K of TECX under a 10b5-1 plan on Aug 25, 2026; 64 funds added in the latest 13F quarter.
McNamara Peter
Chief Scientific Officer
SELL
2026-08-14 SECtraded 2026-08-12
43
$1.5K
-39.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 30, 2026.
  • The trade is 0.1% of the 55,285 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer McNamara Peter sold about $1.5K of TECX on Aug 12, 2026; 64 funds added in the latest 13F quarter.
McNamara Peter
Chief Scientific Officer
SELL
2026-07-01 SECtraded 2026-06-30
172
$6.0K
-46.4%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 6, 2026.
  • The trade is 0.3% of the 55,285 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer McNamara Peter sold about $6.0K of TECX on Jun 30, 2026; 64 funds added in the latest 13F quarter.
Ruddy Marcella K.
Chief Medical Officer
SELL
2026-05-06 SECtraded 2026-05-04
1,065
$31.9K
-24.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 1, 2026.
  • The trade is 1.6% of the 67,682 shares held after it.
  • No other insider sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Ruddy Marcella K. sold about $31.9K of TECX on May 4, 2026; 64 funds added in the latest 13F quarter.
32 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 27 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$53.4K over 180 days
-$15.4K over 90 days
more than 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.7% of the float short (float per yahoo 2026-10-27) · 10.6 days to cover · settled 2026-10-15
more than 76% of Pharma & Biotech
What changed in the last 30 days
Oct 2Chief Scientific Officer McNamara Peter sold $12.3K under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer PETER MCNAMARA filed to sell $11.5K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch TECX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+17.0%12M
-5%+36%+77%+118%2025-102025-122026-022026-042026-062026-082026-10 2026-03-06 · Ruddy Marcella K. sold $300.0K2026-03-06 · McNamara Peter sold $181.4K2026-02-10 · Lochner Daniel bought $129.7K2026-02-11 · REICIN ALISE bought $52.8K2026-03-04 · McNamara Peter sold $41.2K2026-03-03 · McNamara Peter sold $36.4K2026-05-04 · Ruddy Marcella K. sold $31.9K2026-04-01 · Ruddy Marcella K. sold $31.1K2026-09-30 · McNamara Peter sold $12.3K2026-03-06 · McNamara Peter sold $7.5K2026-06-30 · McNamara Peter sold $6.0K2026-08-25 · McNamara Peter sold $1.6K2026-08-12 · McNamara Peter sold $1.5K2026-09-30 · PETER MCNAMARA filed to sell $11.5K2026-08-27 · TERRANCE MCGUIRE filed to sell $276.7K2026-08-21 · TERRANCE MCGUIRE filed to sell $383.7K2026-08-12 · PETER MCNAMARA filed to sell $4.1K2026-06-30 · PETER MCNAMARA filed to sell $5.7K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TECX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
2,830,378 sh
$97.3M
TCG Crossover Management, LLC
1,204,891 sh
$41.4M
Aberdeen Group plc
1,141,824 sh
$39.3M
BlackRock, Inc.
862,592 sh
$29.7M
First Light Asset Management, LLC
800,726 sh
$27.5M

Congress trades in TECX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TECX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
PETER MCNAMARA
Filed 2026-09-30
$11.5K
TERRANCE MCGUIRE
Filed 2026-08-27
$276.7K
TERRANCE MCGUIRE
Filed 2026-08-21
$383.7K
PETER MCNAMARA
Filed 2026-08-12
$4.1K
PETER MCNAMARA
Filed 2026-06-30
$5.7K

TECX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
NORTH SQUARE KENNEDY MICROCAP FUND
$228.0K position · as of 2026-05-31
0.7%
Virtus Biotech Clinical Trials Etf
$287.7K position · as of 2026-07-31
0.6%
AlphaCentric Life Sciences and Healthcare Fund
$238.8K position · as of 2026-06-30
0.5%
ALPS Medical Breakthroughs ETF
$603.1K position · as of 2026-05-31
0.4%
Select Biotechnology Portfolio
$12.6M position · as of 2026-05-31
0.2%
Fidelity Advisor Biotechnology Fund
$3.4M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Erik Ostrowski
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$1.6M
$1.9M
$1.1M
+91%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $53.4K sold by insiders over 180 days, 64 funds added last quarter, $676.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TECX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$72.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.07x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Cash flow to debt
-4.81x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Return on equity
-29,220%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-27,863%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-37.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$185.6M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
FCF yield
-18.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$84.0M-$58.0M-$44.6M-$105.4M
Net income-$74.2B-$58.0B-$42.8B-$105.9M
EPS (diluted)-4.05-6.83-33.76-2.42
Operating cash flow-$60.1M-$59.1M-$40.7M-$97.2M
Cash$253.8M$141.2M$28.8M$92.6M
Long-term debtn/an/an/a$15.0M
SEC XBRL, fiscal years, as known on 2026-10-28

TECX Stock Sonar score 5/7 axes

Find similar shapesCompare

TECX ranks highest on institutional and government (53rd percentile) and financial health (45th), and lowest on risk and compliance (17th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
21
Inputs
  • Return on equity-29220% · 0 pct, sector of 545
  • Return on assets-27863% · 0 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-37.2% · 63 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.07x · 60 pct, sector of 352
  • Cash flow to debt-4.81x · 30 pct, sector of 371
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$39K · 56 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
53
Inputs
  • Funds adding, latest quarter64 · 53 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+18.7% · 17 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TECX filings, in plain words

Are Tectonic Therapeutic insiders buying or selling TECX?

In the 180 days to 2026-10-28, Tectonic Therapeutic insiders were net sellers, a net $53.4K across purchases and sales reported on Form 4, by 2 sellers.

Are there planned insider sales of TECX?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $676.0K of stock; the latest, by PETER MCNAMARA, was filed 2026-09-30.

Read the full summary

In the 180 days to 2026-10-28, Tectonic Therapeutic insiders were net sellers of TECX, a net $53.4K across purchases and sales reported on Form 4 by 2 sellers. 40% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $676.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies